165 related articles for article (PubMed ID: 31785245)
1. Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Vaz RL; Sousa S; Chapela D; van der Linde HC; Willemsen R; Correia AD; Outeiro TF; Afonso ND
Pharmacol Biochem Behav; 2020 Feb; 189():172828. PubMed ID: 31785245
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Cronin A; Grealy M
Neuroscience; 2017 Dec; 367():34-46. PubMed ID: 29079063
[TBL] [Abstract][Full Text] [Related]
3. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
4. Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Feng CW; Wen ZH; Huang SY; Hung HC; Chen CH; Yang SN; Chen NF; Wang HM; Hsiao CD; Chen WF
Zebrafish; 2014 Jun; 11(3):227-39. PubMed ID: 24720843
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
Guo CH; Cao T; Zheng LT; Waddington JL; Zhen XC
Acta Pharmacol Sin; 2020 Apr; 41(4):499-507. PubMed ID: 32112040
[TBL] [Abstract][Full Text] [Related]
6. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
Lundblad M; Andersson M; Winkler C; Kirik D; Wierup N; Cenci MA
Eur J Neurosci; 2002 Jan; 15(1):120-32. PubMed ID: 11860512
[TBL] [Abstract][Full Text] [Related]
8. n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.
Fu RH; Harn HJ; Liu SP; Chen CS; Chang WL; Chen YM; Huang JE; Li RJ; Tsai SY; Hung HS; Shyu WC; Lin SZ; Wang YC
PLoS One; 2014; 9(1):e85305. PubMed ID: 24416384
[TBL] [Abstract][Full Text] [Related]
9. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
Chagniel L; Robitaille C; Lebel M; Cyr M
Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
[TBL] [Abstract][Full Text] [Related]
10. Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
Domenici MR; Potenza RL; Martire A; Coccurello R; Pèzzola A; Reggio R; Tebano MT; Popoli P
J Neurosci Res; 2005 Jun; 80(5):646-54. PubMed ID: 15880742
[TBL] [Abstract][Full Text] [Related]
11. A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons.
Kim GJ; Mo H; Liu H; Wu Z; Chen S; Zheng J; Zhao X; Nucum D; Shortland J; Peng L; Elepano M; Tang B; Olson S; Paras N; Li H; Renslo AR; Arkin MR; Huang B; Lu B; Sirota M; Guo S
Elife; 2021 Sep; 10():. PubMed ID: 34550070
[TBL] [Abstract][Full Text] [Related]
12. Tyrosinyl-amantadine: A New Amantadine Derivative With an Ameliorative Effect in a 6-OHDA Experimental Model of Parkinson's Disease in Rats.
Lazarova M; Tancheva L; Chayrov R; Tzvetanova E; Alexandrova A; Popatanasov A; Uzunova D; Stefanova M; Stankova I; Kalfin R
J Mol Neurosci; 2022 Apr; 72(4):900-909. PubMed ID: 35091981
[TBL] [Abstract][Full Text] [Related]
13. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
Zhao R; Lu W; Fang X; Guo L; Yang Z; Ye N; Zhao J; Liu Z; Jia J; Zheng L; Zhao B; Zhang A; Zhen X
Pharmacol Biochem Behav; 2014 Sep; 124():204-10. PubMed ID: 24955866
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
Cacabelos R
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273839
[TBL] [Abstract][Full Text] [Related]
15. New fraternine analogues: Evaluation of the antiparkinsonian effect in the model of Parkinson's disease.
Mayer AB; Amaral HO; de Oliveira DGR; Campos GAA; Ribeiro PG; Fernandes SCR; de Souza ACB; de Castro RJA; Bocca AL; Mortari MR
Neuropeptides; 2024 Feb; 103():102390. PubMed ID: 37984248
[TBL] [Abstract][Full Text] [Related]
16. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
[TBL] [Abstract][Full Text] [Related]
18. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Pagonabarraga J; Rodríguez-Oroz MC
Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Teixeira FG; Vilaça-Faria H; Domingues AV; Campos J; Salgado AJ
Cells; 2020 Jan; 9(2):. PubMed ID: 32012897
[TBL] [Abstract][Full Text] [Related]
20. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
